The ethics of innovation for Alzheimer's disease: the risk of overstating evidence for metabolic enhancement protocols.
Saved in:
| Title: | The ethics of innovation for Alzheimer's disease: the risk of overstating evidence for metabolic enhancement protocols. |
|---|---|
| Authors: | Daly T; Sorbonne University, Paris, France. timothy.daly@paris-sorbonne.fr., Mastroleo I; National Scientific and Technical Research Council, Buenos Aires, Argentina., Gorski D; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Epelbaum S; Institut du Cerveau et de la Moelle épinière (Brain and Spine Institute), Paris, France. |
| Source: | Theoretical medicine and bioethics [Theor Med Bioeth] 2020 Dec; Vol. 41 (5-6), pp. 223-237. Date of Electronic Publication: 2021 Jan 18. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: Netherlands NLM ID: 9805378 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0980 (Electronic) Linking ISSN: 13867415 NLM ISO Abbreviation: Theor Med Bioeth Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-0980 |
|---|---|
| DOI: | 10.1007/s11017-020-09536-7 |
